Literature DB >> 3865648

Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia.

S Yokoyama, R Hayashi, M Satani, A Yamamoto.   

Abstract

Plasma lipoproteins were selectively removed from familial hypercholesterolemic patients by using two types of plasmapheresis: double-membrane filtration and selective adsorption of very low density lipoproteins (VLDL) and low density lipoproteins (LDL). In both techniques, plasma was separated from blood cells by using hollow-fiber filters, and 100% of the VLDL and LDL was recovered in the filtrate. In double-membrane filtration, the second hollow-fiber filter trapped 84% of LDL + VLDL, 48% of high density lipoprotein (HDL), 24% of albumin, and 46% of the remaining plasma protein. By treating 3 liters of plasma from a patient weighing 60 kg, 60% of the LDL and 30% to 40% of the HDL were removed as a result of an exponential decay of each component with the respective trapping coefficients. When dextran sulfate-cellulose was used as a LDL sorbent, there was only loss of LDL and VLDL, and no loss of any other major plasma component or of HDL. The sorbent column (400 ml) was saturated with 7.5 g of LDL cholesterol by treatment with 3.5 liters of plasma; the maximum reduction of LDL cholesterol was thus about 300 mg/dl for the patient weighing 60 kg. No serious side effects were observed during the long-term trials (19 to 27 months for four patients on double-membrane filtration and 10 months for the two patients on dextran sulfate-cellulose treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3865648     DOI: 10.1161/01.atv.5.6.613

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  32 in total

Review 1.  Incorporation of low-density lipoprotein apheresis into the treatment program of patients with severe hypercholesterolemia.

Authors:  B R Gordon
Journal:  Curr Atheroscler Rep       Date:  2000-07       Impact factor: 5.113

2.  Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis.

Authors:  Yvette C Tanhehco; Ann H Rux; Bruce S Sachais
Journal:  Transfusion       Date:  2010-10-26       Impact factor: 3.157

3.  Effect of LDL-apheresis on the pharmacokinetics of the lipophilic antilipidemic agent probucol.

Authors:  T Komura; K Takahara; M Sugano; A Fujinishi; H Tasaki; Y Nakashima; A Kuroiwa
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.441

4.  Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment.

Authors:  Kurt Derfler; Sabine Steiner; Helmut Sinzinger
Journal:  Wien Klin Wochenschr       Date:  2015-07-23       Impact factor: 1.704

Review 5.  The lipoprotein receptor concept.

Authors:  D W Bilheimer
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Clinical consequences of hyperlipidaemia.

Authors:  G R Thompson
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

7.  Glomerular permselectivity in proteinuric patients after kidney transplantation.

Authors:  R Oberbauer; M Haas; H Regele; U Barnas; A Schmidt; G Mayer
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.

Authors:  Eri Muso; Masatoshi Mune; Tsutomu Hirano; Motoshi Hattori; Kenjiro Kimura; Tsuyoshi Watanabe; Hitoshi Yokoyama; Hiroshi Sato; Shunya Uchida; Takashi Wada; Tetsuo Shoji; Yukio Yuzawa; Tsukasa Takemura; Satoshi Sugiyama; Yoshiki Nishizawa; Satoru Ogahara; Noriaki Yorioka; Soichi Sakai; Yosuke Ogura; Susumu Yukawa; Yasuhiko Iino; Enyu Imai; Seiichi Matsuo; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-06-17       Impact factor: 2.801

9.  Low-density lipoprotein apheresis as a treatment option for hyperlipidemia.

Authors:  Puja K Mehta; Jefferson Baer; Christine Nell; Laurence S Sperling
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

10.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.

Authors:  T Kita; Y Nagano; M Yokode; K Ishii; N Kume; A Ooshima; H Yoshida; C Kawai
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.